Teva Catapults 26% After Scoring A Win In Inflammatory Disease - Investor's Business Daily

Teva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing.

By: Investor's Business Daily

Dec 19 2024
0
0 Views

Teva stock catapulted Tuesday, hitting a six-year high, after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study. XNOW PLAYINGHow To Buy Stocks: 4 Factors F… [+3935 chars]

Turns out everyone in SF didn't need to throw away their black spatulas - SFGATE

Salesforce plans to hire 2,000 people to sell its AI products - TechCrunch

NYC food industry begs for exemption to traffic congestion toll, warns prices will spike: ‘People will stop going out’ - New York Post

The December Federal Reserve Meeting Started Tuesday—What You Need to Know - Investopedia

Insight VC describes Databricks’ wild $10B deal and the bad advice the CEO ignored - TechCrunch

S&P 500 Gains and Losses Today: Health Care Stocks Fall as Trump Eyes 'Middlemen' - Investopedia

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network